Epoetin alfa - Alkermes/Johnson & Johnson

Drug Profile

Epoetin alfa - Alkermes/Johnson & Johnson

Alternative Names: Epoetin alfa - ProLease; Epoetin alpha - Alkermes/Johnson & Johnson; Epoetin alpha - ProLease; r-HuEPO α - Alkermes/Johnson & Johnson; Recombinant human erythropoietin alfa - Alkermes/Johnson & Johnson; Recombinant human erythropoietin alpha - Alkermes/Johnson & Johnson

Latest Information Update: 19 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kirin-Amgen
  • Developer Alkermes; Johnson & Johnson
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 19 Jun 2000 Discontinued-I for Anaemia in USA (SC)
  • 25 Nov 1998 Phase-I clinical trials for Anaemia in USA (SC)
  • 09 Jul 1998 Preclinical development for Anaemia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top